Lidocaine Mucilage-ICG as an Optical Agent for Tumor Delineation During Breast-conserving Surgery
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
Around 15%-30% of patients receiving breast-conserving surgery (BCS) for invasive breast
carcinoma or ductal carcinoma in situ (DCIS) need a reoperation due to tumor-positive margins
at final histopathology. Currently available modalities used for intraoperative surgical
margin assessment all have specific limitations. In order to improve intraoperative tumor
localization and surgical margin assessment in BCS, we developed a fluorescent tracer, the
Lidocaine mucilage-ICG tracer, which could be locally injected and detected by fluorescent
camera systems during operation. In this study, we aim to evaluate the efficacy of Lidocaine
mucilage-ICG as an agent for intraoperative tumor delineation.